in this issue
Regions :: North America :: U.S.
Lonza and BioWa sign license agreements with Pfizer
7:30 AM MDT | July 30, 2013 | Deepti Ramesh
Lonza and BioWa (La Jolla, CA), a wholly owned subsidiary of biopharmaceutical company Kyowa Hakko Kirin (Tokyo), have entered into research agreements with Pfizer allowing the use of the Potelligent CHOK1SV cell line in the R&D of multiple proprietary antibodies in Pfizer’s pipeline, Lonza says. Potelligent CHOK1SV is a host cell line for manufacturing recombinant antibodies. The cell line combines BioWa’s engineered glycosylation Potelligent technology with Lonza’s GS Gene Expression System. The GS system includes Lonza’s...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee